Longitudinal evaluation of adult patients with type 3 SMA with spinal cord imaging and motor scales: in search of new biomarkers.


Topic:

Other

Poster Number: 92 S

Author(s):

FELIPE FRANCO DA GRACA, MD, Universidade Estadual de Campinas (UNICAMP), Cristina Iwabe, PhD, Universidade Estadual de Campinas (UNICAMP), Thiago Junqueira Ribeiro de Rezende, PhD, Universidade Estadual de Campinas (UNICAMP), Marcondes Cavalcante França Jr, MD PhD, Universidade Estadual de Campinas (UNICAMP)

Spinal muscular atrophy (SMA) is an autosomal recessive lower motor neuron disorder caused by biallelic loss-of-function variants in SMN1. SMA type 3 is a milder phenotype in which patients remain ambulant, subdivided into type 3a (onset <3 years) and 3b (onset >3 years). While natural history is well established for types 1 and 2, the clinical course of late-onset patients remains insufficiently characterized, representing a limitation in their management—especially in the current context of effective disease-modifying therapies.

This study included adult SMA type 3 patients confirmed by genetic testing who were able to undergo MRI, along with an equal number of age-matched healthy controls. All subjects were scanned on a 3T Phillips Achieva system using a 16-channel neurovascular coil in two visits one year apart. Axial-oblique images were acquired at the C2–C3 level, and cross-sectional area (CSA) and gray matter (GM) area were automatically segmented with a deep-learning algorithm. MRI processing was performed using Spinal Cord Toolbox v4.0.1.

Seventeen adults with SMA type 3 (12 men, 5 women; mean age 32.1 years) were evaluated. CSA at C3 showed no significant difference between visits in patients (p=0.89) nor between patients and controls (p=0.20). GM area similarly showed no significant longitudinal change, but the comparison between patients and controls demonstrated a marked difference (p<0.0001). When combined with clinical measures, GM area strongly correlated with MFM scores (r=0.79, p=0.0002). These findings reinforce that SMA-related pathology is concentrated in spinal gray matter and, for the first time, demonstrate that GM area measured non-invasively by MRI correlates almost linearly with motor function. GM quantification thus emerges as a promising biomarker in adult SMA patients.